Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: A pilot trial

Lung Cancer

Volumn 45, Issue 3, 2004, Pages 365-371

  Pless, Miklos ^a   Waldherr, Christian ^a   Maecke, Helmut ^a   Buitrago, Carlos ^a   Herrmann, Richard ^a   Mueller Brand, Jan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Octreoscan scintigraphy; Somatostatin receptor

Indexed keywords

ANTINEOPLASTIC AGENT; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] Y 90; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HUMAN; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MEDIASTINUM DISEASE; NEPHROTOXICITY; PRIORITY JOURNAL; SCINTIGRAPHY; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 3843138512     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.02.020     Document Type: Article

References (30)

1. Reubi J.C., Waser B., Sheppard M., Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 45:1990;269-274
2. Sagman U., Mullen J.B., Kovacs K., Kerbel R., Ginsberg R., Reubi J.C. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer. 66:1990;2129-2133
3. Lamberts S.W., Bakker W.H., Reubi J.C., Krenning E.P. Somatostatin-receptor imaging in the localization of endocrine tumors [see comments]. N Engl J Med. 323:1990;1246-1249
4. Pantev T., Virgolini I., Neuhold N., Angelberger P., Luger A., Sinzinger H. Evaluation of somatostatin receptors in human cancer. Wien Klin Wochenschr. 103:1991;649-653
5. De Jong M., Bakker W.H., Krenning E.P., Breeman W.A., van der Pluijm M.E., Bernard B.F., et al. Yttrium-90 and indium-111 labelling, receptor binding and bio-distribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 24:1997;368-371
6. Otte A., Jermann E., Behe M., Goetze M., Bucher H.C., Roser H.W., et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 24:1997;792-795
7. Waldherr C., Pless M., Maecke H.R., Schumacher T., Crazzolara A., Nitzsche E.U., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 43:2002;610-616
8. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 351:1998;417-418
9. Paganelli G., Zoboli S., Cremonesi M., Bodei L., Ferrari M., Grana C., et al. Orsi F, Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3- octreotide. Eur J Nucl Med. 28:2001;426-434
10. Chinol M., Bodei L., Cremonesi M., Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med. 32:2002;141-147
11. Otte A., Herrmann R., Macke H.R., Muller-Brand J. Yttrium 90-DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors. Schweiz Rundsch Med Prax. 88:1999;1263-1268
12. Tilmann S., Waldherr C., Mueller-Brand J., Maecke H. Kidney failure after treatment with 90Y-DOTATOC. Eur J Nucl Med Mol Imaging. 29:2002;435
13. Otte A., Cybulla M., Weiner S.M. 90Y-DOTATOC and nephrotoxicity. Eur J Nucl Med Mol Imaging. 29:2002;1543
14. Moll S., Nickeleit V., Mueller-Brand J., Brunner F.P., Maecke H.R., Mihatsch M.J. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 37:2001;847-851
15. 90Y -DOTATOC Eur J Nucl Med. 28:2001;1552-1554
16. 90Y ]-DOTA-D-Phe1-Try3-octreotide: a pilot study Nucl Med Commun. 22:2001;673-678
17. 90Y -DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann Oncol. 12:2001;941-945
18. 90Y -labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas Clin Cancer Res. 12:1999;1025-1033
19. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 17:1999;658-667
20. Berenger N., Moretti J.L., Boaziz C., Vigneron N., Morere J.F., Breau J.L. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer. 32A:1996;1429-1431
21. 111In -DTPA octreotide scintigraphy Eur J Cancer. 31A:1995;184-188
22. Bohuslavizki K.H., Brenner W., Gunther M., Eberhardt J.U., Jahn N., Tinnemeyer S., et al. Somatostatin receptor scintigraphy in the staging of small cell lung cancer. Nucl Med Commun. 17:1996;191-196
23. 111In octreotide imaging in staging of small cell lung cancer Clin Nucl Med. 22:1997;811-816
24. Kwekkeboom D.J., Kho G.S., Lamberts S.W., Reubi J.C., Laissue J.A., Krenning E.P. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 21:1994;1106-1113
25. Reisinger I., Bohuslavitzki K.H., Brenner W., Braune S., Dittrich I., Geide A., et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med. 39:1998;224-227
26. 111In ] pentetreotide, a radio-labelled somatostatin analogue Br J Cancer. 69:1994;762-766
27. Macaulay V.M., Smith I.E., Everard M.J., Teale J.D., Reubi J.C., Millar J.L. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer. 64:1991;451-456
28. Marschke R.F. Jr., Grill J.P., Sloan J.A., Wender D.B., Levitt R., Mailliard J.A., et al. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol. 22:1999;15-17
29. 90Y -SMT487 (Octreother) therapy J Nucl Med. 41:2000;111P
30. Behr T.M., Behe M.P. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 32:2002;97-109